SciClone Pharmaceuticals (Holdings) Limited (HK:6600) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SciClone Pharmaceuticals (Holdings) Limited has announced that 12,500 Share Options from its Post-IPO Option Plan have lapsed as of June 15, 2024, according to the plan’s rules. Following this lapse, the company reports a total of 630,543,012 Shares in issue and 66,218,552 Share Options still in issue, comprised of different tranches under its Option Incentive and Post-IPO Option Plans.
For further insights into HK:6600 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue